Molecular Analysis for Therapy Choice (MATCH) - MATCH Treatment Subprotocol I: GDC_0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA Mutation but without KRAS Mutation or PTEN Loss

Protocol: 
AAAP9159
Phase: 
I

Molecular Analysis for Therapy Choice (MATCH) - MATCH Treatment Subprotocol I: GDC_0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA Mutation but without KRAS Mutation or PTEN Loss

To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas.

Are you Eligible? (Inclusion Criteria)

Patients must be >= 18 years of age.
Patients with advanced refractory cancers/lymphomas

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States